C. B. Mather

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

J. Nemunaitis, R. Benner, C. Belani, 2013, Cancer biology & therapy.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

P. Jänne, K. O'Byrne, T. Mok, 2014, The Lancet. Oncology.

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

M. Millward, J. Gómez-Navarro, M Millward, 2013, British Journal of Cancer.